DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,824,047 | +17.6% | 15,413 | +13.8% | 0.64% | +19.4% |
| Q2 2023 | $3,250,395 | -4.1% | 13,543 | +0.7% | 0.54% | -11.0% |
| Q1 2023 | $3,388,248 | -4.7% | 13,443 | +0.3% | 0.60% | -6.5% |
| Q4 2022 | $3,556,702 | +5.6% | 13,400 | +2.8% | 0.64% | -6.3% |
| Q3 2022 | $3,368,000 | -1.1% | 13,040 | -2.9% | 0.69% | +6.0% |
| Q2 2022 | $3,404,000 | -16.1% | 13,426 | -3.0% | 0.65% | +5.4% |
| Q1 2022 | $4,058,000 | -10.9% | 13,835 | -0.1% | 0.61% | -13.6% |
| Q4 2021 | $4,555,000 | +7.9% | 13,845 | -0.2% | 0.71% | -3.3% |
| Q3 2021 | $4,223,000 | +6.7% | 13,870 | -5.9% | 0.74% | +9.1% |
| Q2 2021 | $3,957,000 | +10.3% | 14,745 | -7.5% | 0.67% | +2.9% |
| Q1 2021 | $3,589,000 | -6.8% | 15,945 | -8.0% | 0.66% | -13.9% |
| Q4 2020 | $3,851,000 | +6.3% | 17,335 | +3.0% | 0.76% | -10.4% |
| Q3 2020 | $3,623,000 | +20.0% | 16,825 | -1.5% | 0.85% | -10.4% |
| Q2 2020 | $3,019,000 | +21.3% | 17,075 | -5.0% | 0.95% | +10.6% |
| Q1 2020 | $2,488,000 | -11.2% | 17,975 | -1.5% | 0.86% | +14.4% |
| Q4 2019 | $2,801,000 | +13.1% | 18,250 | +6.4% | 0.75% | +3.9% |
| Q3 2019 | $2,477,000 | +0.6% | 17,150 | -0.4% | 0.72% | +1.4% |
| Q2 2019 | $2,462,000 | +4.3% | 17,225 | -3.6% | 0.71% | 0.0% |
| Q1 2019 | $2,360,000 | +26.3% | 17,875 | -1.4% | 0.71% | +19.7% |
| Q4 2018 | $1,869,000 | -6.1% | 18,125 | -1.1% | 0.59% | +4.2% |
| Q3 2018 | $1,991,000 | +10.1% | 18,325 | 0.0% | 0.57% | +0.4% |
| Q2 2018 | $1,808,000 | +3.4% | 18,325 | +2.7% | 0.57% | -9.1% |
| Q1 2018 | $1,748,000 | +4.4% | 17,850 | -1.1% | 0.62% | +4.7% |
| Q4 2017 | $1,675,000 | +7.6% | 18,050 | -0.6% | 0.60% | +1.7% |
| Q3 2017 | $1,557,000 | +1.5% | 18,150 | -0.1% | 0.59% | -4.7% |
| Q2 2017 | $1,534,000 | -5.7% | 18,175 | -4.5% | 0.62% | -2.2% |
| Q1 2017 | $1,627,000 | +2.7% | 19,025 | -6.5% | 0.63% | 0.0% |
| Q4 2016 | $1,584,000 | -2.2% | 20,350 | -1.5% | 0.63% | -9.0% |
| Q3 2016 | $1,619,000 | -22.4% | 20,650 | 0.0% | 0.69% | -22.8% |
| Q2 2016 | $2,086,000 | +4.9% | 20,650 | -1.5% | 0.90% | +4.6% |
| Q1 2016 | $1,988,000 | +3.1% | 20,955 | +1.0% | 0.86% | -1.0% |
| Q4 2015 | $1,928,000 | +9.0% | 20,756 | +0.0% | 0.87% | +11.2% |
| Q3 2015 | $1,769,000 | +1.4% | 20,755 | +1.9% | 0.78% | +7.9% |
| Q2 2015 | $1,744,000 | -0.4% | 20,375 | -1.2% | 0.72% | +4.2% |
| Q1 2015 | $1,751,000 | +0.9% | 20,625 | +1.9% | 0.69% | +3.0% |
| Q4 2014 | $1,736,000 | +13.2% | 20,250 | +0.4% | 0.67% | +6.8% |
| Q3 2014 | $1,533,000 | -3.9% | 20,175 | -0.5% | 0.63% | -8.7% |
| Q2 2014 | $1,596,000 | +5.5% | 20,275 | +0.5% | 0.69% | +3.0% |
| Q1 2014 | $1,513,000 | -3.1% | 20,175 | -0.2% | 0.67% | -4.7% |
| Q4 2013 | $1,561,000 | +11.3% | 20,225 | 0.0% | 0.70% | +4.0% |
| Q3 2013 | $1,402,000 | +8.2% | 20,225 | -1.2% | 0.68% | +5.3% |
| Q2 2013 | $1,296,000 | – | 20,475 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |